PHILADELPHIA and SHANGHAI, China, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (the “Company”), a women’s oncology company developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers, and Tyligand Bioscience, Ltd. (“Tyligand”), a leader in small molecule drug discovery and development, today announced the successful completion of ONA-XR (onapristone extended release) manufacturing process optimization pursuant to the collaboration agreement entered into between the parties in March 2020.